Annual Conference & Webinar Schedule
To learn more about NP Thyroid®, please visit the Acella Pharmaceuticals booth at the events listed below. Acella also invites you to attend our product theater sessions.
By clicking "Register" below, you will be redirected to the event host’s website, where you can complete your registration.
JANUARY
Clinical Diabetes & Endocrinology Institute Annual
(CDEI)
January 23-26, 2026 – Vail, CO
Table #: 28
APRIL
A4M Spring
April 10-12, 2026 – West Palm Beach, FL
Booth #: 247
American Association of Clinical Endocrinology Annual Meeting (AACE)
April 22-24, 2026 – Las Vegas, NV
Booth #: 108
Product Theater
Thursday, April 23 at 2:30-3:15 PM ET
Title
TBD
MAY
American Academy of Physician Associates 2026 (AAPA)
May 15-19, 2026 – New Orleans, LA
Booth #: TBD
Product Theater
Saturday, May 16 at 11:45 AM-12:45 PM CT with speakers Jaime Ginney, PA-C and Olivia Crimmins,
PA-C
Title
TBD
AIC 2026 - IFM's Functional Medicine Conference
May 27-30, 2026 – San Diego, CA
Booth #: 722
Product Theater
Friday, May 29 at 6:45-7:45 AM PT with speaker Angela Mazza, DO
Title
TBD
JUNE
Endocrine Society's Annual Meeting 2026 (ENDO)
June 13-16, 2026 – Chicago, IL
Booth #: TBD
Product Theater
Saturday, June 13 at 12:30-1:30 PM CT
Title
TBD
American Association of Nurse Practitioners (AANP)
June 23-28, 2026 – Las Vegas, Nevada
Booth #: TBD
Product Theater
Wednesday, June 24 at 11:45 AM-1:00 PM PT
Title
TBD
September
Texas Nurse Practitioners Annual Fall Conference (TNP)
September 24-27, 2026 – San Antonio, Texas
Booth #: TBD
Product Theater
Friday, September 25 at 7:45- 8:45 AM CT
Title
TBD
October
New York Nurse Practitioners Association (NPA)
October 1-4, 2026 – Niagara Falls, NY
Booth #: TBD
Mid-Atlantic Society of Endocrinologists 2025 Annual Meeting (MASE)
TBD – Hyattesville, MD
Booth #: TBD
Michigan Council of Nurse Practitioners Annual Conference (MICNP)
TBD – Michigan
Booth #: TBD
November
American Thyroid Association (ATA)
November 4-7, 2026 – Philadelphia, PA
Booth #: TBD
December
A4M Winter
December 11-13, 2026 – Las Vegas, NV
Booth #: 474
You Are About To Leave This Website
By clicking continue, this link will take you to a website to which Alora Pharmaceuticals’ Policies & Terms of Use do not apply.
You Are About To Leave This Website
By clicking continue, this link will take you to a website to which Alora Pharmaceuticals’ Policies & Terms of Use do not apply. Alora and its subsidiaries do not control the content or accuracy of third-party websites and assume no responsibility for their use.
Note that DTE products, including NP Thyroid®, have not been reviewed by the FDA for safety or efficacy.
IMPORTANT RISK INFORMATION, INCLUDING BOXED WARNING & INDICATIONS
Important Risk Information
Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
- NP Thyroid® is contraindicated in patients with uncorrected adrenal insufficiency, untreated thyrotoxicosis, and hypersensitivity to any component of the product.
- In the elderly and in patients with cardiovascular disease, NP Thyroid® should be used with greater caution than younger patients or those without cardiovascular disease.
- Use of NP Thyroid® in patients with diabetes mellitus or adrenal cortical insufficiency may worsen the intensity of their symptoms.
- The therapy of myxedema coma requires simultaneous administration of glucocorticoids.
- Concomitant use of NP Thyroid® with oral anticoagulants alters the sensitivity of oral anticoagulants. Prothrombin time should be closely monitored in thyroid-treated patients on oral anticoagulants.
- In infants, excessive doses of NP Thyroid® may produce craniosynostosis.
- Partial loss of hair may be experienced by children in the first few months of therapy but is usually transient.
- Adverse reactions associated with NP Thyroid® therapy are primarily those of hyperthyroidism due to therapeutic overdosage.
- Many drugs and some laboratory tests may alter the therapeutic response to NP Thyroid®. In addition, thyroid hormones and thyroid status have varied effects on the pharmacokinetics and actions of other drugs. Administer at least 4 hours before or after drugs that are known to interfere with absorption. Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption.
- NP Thyroid® should not be discontinued during pregnancy, and hypothyroidism diagnosed during pregnancy should be promptly treated.
Indications
NP Thyroid® (thyroid tablets, USP) is a prescription medicine that is used to treat a condition called hypothyroidism from any cause, except for cases of temporary hypothyroidism, which is usually associated with an inflammation of the thyroid (thyroiditis). It is meant to replace or supplement a hormone that is usually made by your thyroid gland.
NP Thyroid® is also used in the treatment and prevention of normal functioning thyroid
goiters, such as thyroid nodules, Hashimoto’s thyroiditis, multinodular goiter, and in the
management of thyroid cancer.
Revised 10/2023